304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2021-05-13

Henlius Will Release the RA Phase 3 Clinical Study Results of Its Rituximab Injection HLX01 at Two Congresses
2021-05-11

Henlius Entered into a Collaboration with NeuPharma of a BRAF Target Inhibitor
2021-05-10

Henlius will Release Two Clinical Studies of anti-PD-1 mAb Serplulimab in 2021 ASCO
2021-04-29

Biodrugs Published the Results of the International Multicentre Phase 3 Clinical Trial of 汉曲优®
2021-04-22

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review
2021-04-20

Application for Clinical Trial of Henlius Bevacizumab HLX04-O Has Been Approved for the Treatment of wAMD in Latvia
2021-04-15

Henlius Received IND Approval for Its Novel Anti-LAG-3 mAb HLX26 from NMPA
2021-04-14

First Subject Dosed in Phase 1 Clinical Trial of Henlius COVID-19 Drug Candidate HLX71 in the US
2021-03-29

Making Most out of Launched Products, Fueling Diversified Innovation through Integrated Platform